Roles of Obese-Insulin Resistance and Anti-Diabetic Drugs on the Heart with Ischemia-Reperfusion Injury

Cardiovascular Drugs and Therapy

Volumn 28, Issue 6, 2014, Pages 549-562

  Apaijai, Nattayaporn ^a   Chattipakorn, Siriporn C ^a   Chattipakorn, Nipon ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Infarct size; Insulin resistance; Ischemia reperfusion injury; Left ventricular function; Obesity

Indexed keywords

6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ANTIDIABETIC AGENT; CYCLOSPORIN A; CYTOKINE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ERYTHROPOIETIN; HEAT SHOCK PROTEIN 72; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; KERATINOCYTE DERIVED CHEMOKINE; LOSARTAN; MATRIX METALLOPROTEINASE; MELATONIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PFK 275 055; PIOGLITAZONE; RESVERATROL; ROSIGLITAZONE; TEPRENONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CALORIC INTAKE; CARBOHYDRATE DIET; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG MECHANISM; GENE DELETION; GLUCOSE UTILIZATION; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; HYPERINSULINEMIA; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; ISCHEMIC POSTCONDITIONING; LIPID DIET; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NONHUMAN; OBESITY; REPERFUSION INJURY; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL; TREADMILL EXERCISE; ANIMAL; DRUG EFFECTS; HEART; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; HEART; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; OBESITY; REPERFUSION INJURY;

EID: 84916207996     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-014-6553-6     Document Type: Article

References (74)

1. Jequier E. Obesity. Impairment of energy intake or of energy expenditure. Ann Endocrinol (Paris). 1995;56(2):87–92.
2. Pratchayasakul W, Kerdphoo S, Petsophonsakul P, Pongchaidecha A, Chattipakorn N, Chattipakorn SC. Effects of high-fat diet on insulin receptor function in rat hippocampus and the level of neuronal corticosterone. Life Sci. 2011;88(13–14):619–27.
3. Beck B. Neuropeptide Y, in normal eating and in genetic and dietary-induced obesity. Philos Trans R Soc Lond B Biol Sci. 2006;361(1471):1159–85.
4. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173–94.
5. Matsuzawa-Nagata N, Takamura T, Ando H, Nakamura S, Kurita S, Misu H, et al. Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. Metabolism. 2008;57(8):1071–7.
6. West DB, York B. Dietary fat, genetic predisposition, and obesity: lessons from animal models. Am J Clin Nutr. 1998;67(3 Suppl):505S–12.
7. Fujita H, Kang M, Eren M, Gleaves LA, Vaughan DE, Kume T. Foxc2 is a common mediator of insulin and transforming growth factor beta signaling to regulate plasminogen activator inhibitor type I gene expression. Circ Res. 2006;98(5):626–34.
8. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev. 2007;12(3–4):217–34.
9. Carillon J, Romain C, Bardy G, Fouret G, Feillet-Coudray C, Gaillet S, et al. Cafeteria diet induces obesity and insulin resistance associated with oxidative stress but not with inflammation: improvement by dietary supplementation with a melon superoxide dismutase. Free Radic Biol Med. 2013;65C:254–61.
10. Liu J, Lloyd SG. High-fat, low-carbohydrate diet alters myocardial oxidative stress and impairs recovery of cardiac function after ischemia and reperfusion in obese rats. Nutr Res. 2013;33(4):311–21.
11. Miura T, Tanno M. Mitochondria and GSK-3beta in cardioprotection against ischemia/reperfusion injury. Cardiovasc Drugs Ther. 2010;24(3):255–63.
12. Miura T, Tanno M. The mPTP and its regulatory proteins: final common targets of signalling pathways for protection against necrosis. Cardiovasc Res. 2012;94(2):181–9.
13. Ghaboura N, Tamareille S, Ducluzeau PH, Grimaud L, Loufrani L, Croue A, et al. Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3beta signaling. Basic Res Cardiol. 2011;106(1):147–62.
14. Honda T, Kaikita K, Tsujita K, Hayasaki T, Matsukawa M, Fuchigami S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders. J Mol Cell Cardiol. 2008;44(5):915–26.
15. Huisamen B, Genis A, Marais E, Lochner A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther. 2011;25(1):13–20.
16. Yue TL, Nerurkar SS, Bao W, Jucker BM, Sarov-Blat L, Steplewski K, et al. In vivo activation of peroxisome proliferator-activated receptor-delta protects the heart from ischemia/reperfusion injury in Zucker fatty rats. J Pharmacol Exp Ther. 2008;325(2):466–74.
17. Cardenas G, Torres JC, Zamora J, Banos G. Isolated heart function during ischemia and reperfusion in sucrose- fed rats: effect of insulin infusion. Cardiovasc Pathol. 2005;14(5):256–64.
18. Gundewar S, Calvert JW, Elrod JW, Lefer DJ. Cytoprotective effects of N, N, N-trimethylsphingosine during ischemia- reperfusion injury are lost in the setting of obesity and diabetes. Am J Physiol Heart Circ Physiol. 2007;293(4):H2462–71.
19. Huisamen B, Perel SJ, Friedrich SO, Salie R, Strijdom H, Lochner A. ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance. Mol Cell Biochem. 2011;349(1–2):21–31.
20. Lekli I, Szabo G, Juhasz B, Das S, Das M, Varga E, et al. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol. 2008;294(2):H859–66.
21. Nduhirabandi F, Du Toit EF, Blackhurst D, Marais D, Lochner A. Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity. J Pineal Res. 2011;50(2):171–82.
22. Ooie T, Kajimoto M, Takahashi N, Shinohara T, Taniguchi Y, Kouno H, et al. Effects of insulin resistance on geranylgeranylacetone-induced expression of heat shock protein 72 and cardioprotection in high-fat diet rats. Life Sci. 2005;77(8):869–81.
23. Bouhidel O, Pons S, Souktani R, Zini R, Berdeaux A, Ghaleh B. Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Am J Physiol Heart Circ Physiol. 2008;295(4):H1580–6.
24. Donner D, Headrick JP, Peart JN, du Toit EF. Obesity improves myocardial ischaemic tolerance and RISK signalling in insulin-insensitive rats. Dis Model Mech. 2013;6(2):457–66.
25. du Toit EF, Nabben M, Lochner A. A potential role for angiotensin II in obesity induced cardiac hypertrophy and ischaemic/reperfusion injury. Basic Res Cardiol. 2005;100(4):346–54.
26. Huang JV, Lu L, Ye S, Bergman BC, Sparagna GC, Sarraf M, et al. Impaired contractile recovery after low-flow myocardial ischemia in a porcine model of metabolic syndrome. Am J Physiol Heart Circ Physiol. 2013;304(6):H861–73.
27. Huhn R, Heinen A, Hollmann MW, Schlack W, Preckel B, Weber NC. Cyclosporine a administered during reperfusion fails to restore cardioprotection in prediabetic Zucker obese rats in vivo. Nutr Metab Cardiovasc Dis. 2010;20(10):706–12.
28. Jordan JE, Simandle SA, Tulbert CD, Busija DW, Miller AW. Fructose-fed rats are protected against ischemia/reperfusion injury. J Pharmacol Exp Ther. 2003;307(3):1007–11.
29. Lacerda L, Opie LH, Lecour S. Influence of tumour necrosis factor alpha on the outcome of ischaemic postconditioning in the presence of obesity and diabetes. Exp Diabetes Res. 2012;2012:502654.
30. Lacerda L, Somers S, Opie LH, Lecour S. Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res. 2009;84(2):201–8.
31. Pons S, Martin V, Portal L, Zini R, Morin D, Berdeaux A, et al. Regular treadmill exercise restores cardioprotective signaling pathways in obese mice independently from improvement in associated co-morbidities. J Mol Cell Cardiol. 2013;54:82–9.
32. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes. 2002;51(4):1110–7.
33. Song T, Lv LY, Xu J, Tian ZY, Cui WY, Wang QS, et al. Diet-induced obesity suppresses sevoflurane preconditioning against myocardial ischemia-reperfusion injury: role of AMP-activated protein kinase pathway. Exp Biol Med (Maywood). 2011;236(12):1427–36.
34. Thakker GD, Frangogiannis NG, Zymek PT, Sharma S, Raya JL, Barger PM, et al. Increased myocardial susceptibility to repetitive ischemia with high-fat diet-induced obesity. Obesity (Silver Spring). 2008;16(12):2593–600.
35. Wensley I, Salaveria K, Bulmer AC, Donner DG, Du Toit EF. Myocardial structure, function, and ischaemic tolerance in a rodent model of obesity with insulin resistance. Exp Physiol. 2013;98(11):1552–64.
36. Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chronic Dis. 1979;32(8):563–76.
37. Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the nutrition committee, American heart association. Circ. 1997;96(9):3248–50.
38. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121–35.
39. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013;123(1):92–100.
40. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793–801.
41. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem. 2000;275(12):9047–54.
42. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11(2):183–90.
43. De Fea K, Roth RA. Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase. J Biol Chem. 1997;272(50):31400–6.
44. Gual P, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie. 2005;87(1):99–109.
45. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res. 1997;33(2):243–57.
46. van den Brom CE, Bulte CS, Loer SA, Bouwman RA, Boer C. Diabetes, perioperative ischaemia and volatile anaesthetics: consequences of derangements in myocardial substrate metabolism. Cardiovasc Diabetol. 2013;12:42.
47. Galgani JE, Moro C, Ravussin E. Metabolic flexibility and insulin resistance. Am J Physiol Endocrinol Metab. 2008;295(5):E1009–17.
48. Deng JY, Huang JP, Lu LS, Hung LM. Impairment of cardiac insulin signaling and myocardial contractile performance in high-cholesterol/fructose-fed rats. Am J Physiol Heart Circ Physiol. 2007;293(2):H978–87.
49. Carley AN, Severson DL. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta. 2005;1734(2):112–26.
50. Bopassa JC, Michel P, Gateau-Roesch O, Ovize M, Ferrera R. Low-pressure reperfusion alters mitochondrial permeability transition. Am J Physiol Heart Circ Physiol. 2005;288(6):H2750–5.
51. Sarti P, Silver RB, Paroli L, Nikonorov I, Blanck TJ. Permeability of rat heart myocytes to cytochrome c. Cell Mol Life Sci. 1999;56(11–12):1061–9.
52. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251–62.
53. Solskov L, Lofgren B, Kristiansen SB, Jessen N, Pold R, Nielsen TT, et al. Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration. Basic Clin Pharmacol Toxicol. 2008;103(1):82–7.
54. Tanno M, Bassi R, Gorog DA, Saurin AT, Jiang J, Heads RJ, et al. Diverse mechanisms of myocardial p38 mitogen-activated protein kinase activation: evidence for MKK-independent activation by a TAB1-associated mechanism contributing to injury during myocardial ischemia. Circ Res. 2003;93(3):254–61.
55. Quindry JC, Hamilton KL, French JP, Lee Y, Murlasits Z, Tumer N, et al. Exercise-induced HSP-72 elevation and cardioprotection against infarct and apoptosis. J Appl Physiol (1985). 2007;103(3):1056–62.
56. Ravagnan L, Gurbuxani S, Susin SA, Maisse C, Daugas E, Zamzami N, et al. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol. 2001;3(9):839–43.
57. Joshy G, Korda RJ, Attia J, Liu B, Bauman AE, Banks E. Body mass index and incident hospitalisation for cardiovascular disease in 158 546 participants from the 45 and Up study. Int J Obes (Lond). 2014;38(6):848–56.
58. Andersson C, van Gaal L, Caterson ID, Weeke P, James WP, Coutinho W, et al. Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia. 2012;55(9):2348–55.
59. Poyraz F, Turfan M, Kocaman SA, Yazici HU, Sen N, Tulmac M, et al. Effect of overweight and obesity on the left ventricular systolic and diastolic functions in patients with acute myocardial infarction. Clin Invest Med. 2012;35(4):E229–36.
60. Kadakia MB, Fox CS, Scirica BM, Murphy SA, Bonaca MP, Morrow DA. Central obesity and cardiovascular outcomes in patients with acute coronary syndrome: observations from the MERLIN-TIMI 36 trial. Heart. 2011;97(21):1782–7.
61. Lee SH, Park JS, Kim W, Shin DG, Kim YJ, Kim DS, et al. Impact of body mass index and waist-to-hip ratio on clinical outcomes in patients with ST-segment elevation acute myocardial infarction (from the Korean acute myocardial infarction registry). Am J Cardiol. 2008;102(8):957–65.
62. Gastelurrutia P, Pascual-Figal D, Vazquez R, Cygankiewicz I, Shamagian LG, Puig T, et al. Obesity paradox and risk of sudden death in heart failure results from the MUerte subita en insuficiencia cardiaca (MUSIC) study. Am Heart J. 2011;161(1):158–64.
63. Kragelund C, Hassager C, Hildebrandt P, Torp-Pedersen C, Kober L. Impact of obesity on long-term prognosis following acute myocardial infarction. Int J Cardiol. 2005;98(1):123–31.
64. Wu AH, Pitt B, Anker SD, Vincent J, Mujib M, Ahmed A. Association of obesity and survival in systolic heart failure after acute myocardial infarction: potential confounding by age. Eur J Heart Fail. 2010;12(6):566–73.
65. Choy B, Hansen E, Moss AJ, McNitt S, Zareba W, Goldenberg I. Relation of body mass index to sudden cardiac death and the benefit of implantable cardioverter-defibrillator in patients with left ventricular dysfunction after healing of myocardial infarction. Am J Cardiol. 2010;105(5):581–6.
66. Pingitore A, Di Bella G, Lombardi M, Iervasi G, Strata E, Aquaro GD, et al. The obesity paradox and myocardial infarct size. J Cardiovasc Med (Hagerstown). 2007;8(9):713–7.
67. Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-Dehoff RM, Zhou Q, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med. 2007;120(10):863–70.
68. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2001;38(3):789–95.
69. Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 2013;1(2):93–102.
70. Khattab AA, Daemen J, Richardt G, Rioux P, Amann FW, Levy R, et al. Impact of body mass index on the one- year clinical outcome of patients undergoing multivessel revascularization with sirolimus-eluting stents (from the arterial revascularization therapies study part II). Am J Cardiol. 2008;101(11):1550–9.
71. Kosuge M, Kimura K, Kojima S, Sakamoto T, Ishihara M, Asada Y, et al. Impact of body mass index on in- hospital outcomes after percutaneous coronary intervention for ST segment elevation acute myocardial infarction. Circ J. 2008;72(4):521–5.
72. Sarno G, Raber L, Onuma Y, Garg S, Brugaletta S, van Domburg RT, et al. Impact of body mass index on the five-year outcome of patients having percutaneous coronary interventions with drug-eluting stents. Am J Cardiol. 2011;108(2):195–201.
73. Stochmal A, Jasiak-Tyrkalska B, Stochmal E, Huszno B, Kawecka-Jaszcz K. The influence of physical training on metabolic indices in men with myocardial infarction and impaired glucose tolerance. Przegl Lek. 2007;64(6):410–5.
74. Wee CC, Girotra S, Weinstein AR, Mittleman MA, Mukamal KJ. The relationship between obesity and atherosclerotic progression and prognosis among patients with coronary artery bypass grafts the effect of aggressive statin therapy. J Am Coll Cardiol. 2008;52(8):620–5.